Meyka Pro banner
Exagen Inc.

Exagen Inc. Fundamental Analysis (NASDAQ: XGN)

XGN●NASDAQ
HealthcareMedical - Diagnostics & Research
$3.77
$0.36(8.72%)
U.S. Market opens in NaNh NaNm

Exagen Inc. Fundamental Analysis (NASDAQ: XGN)

Exagen Inc. (NASDAQ: XGN) shows moderate financial fundamentals with a PE ratio of -4.99, profit margin of -25.14%, and ROE of -1.26%. The company generates $0.1B in annual revenue with strong year-over-year growth of 19.65%.

Key Strengths

Cash Position29.99%
PEG Ratio-0.26
Current Ratio3.46

Areas of Concern

ROE-1.26%
Operating Margin-20.08%
We analyze XGN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -115.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-115.6/100

We analyze XGN's fundamental strength across five key dimensions:

Efficiency Score

Weak

XGN struggles to generate sufficient returns from assets.

ROA > 10%
-32.83%

Valuation Score

Excellent

XGN trades at attractive valuation levels.

PE < 25
-4.99
PEG Ratio < 2
-0.26

Growth Score

Moderate

XGN shows steady but slowing expansion.

Revenue Growth > 5%
19.65%
EPS Growth > 10%
-12.05%

Financial Health Score

Moderate

XGN shows balanced financial health with some risks.

Debt/Equity < 1
2.09
Current Ratio > 1
3.46

Profitability Score

Weak

XGN struggles to sustain strong margins.

ROE > 15%
-125.60%
Net Margin ≥ 15%
-25.14%
Positive Free Cash Flow
No

Key Financial Metrics

Is XGN Expensive or Cheap?

P/E Ratio

XGN trades at -4.99 times earnings. This suggests potential undervaluation.

-4.99

PEG Ratio

When adjusting for growth, XGN's PEG of -0.26 indicates potential undervaluation.

-0.26

Price to Book

The market values Exagen Inc. at 6.85 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.85

EV/EBITDA

Enterprise value stands at -8.51 times EBITDA. This is generally considered low.

-8.51

How Well Does XGN Make Money?

Net Profit Margin

For every $100 in sales, Exagen Inc. keeps $-25.14 as profit after all expenses.

-25.14%

Operating Margin

Core operations generate -20.08 in profit for every $100 in revenue, before interest and taxes.

-20.08%

ROE

Management delivers $-1.26 in profit for every $100 of shareholder equity.

-1.26%

ROA

Exagen Inc. generates $-32.83 in profit for every $100 in assets, demonstrating efficient asset deployment.

-32.83%

Following the Money - Real Cash Generation

Operating Cash Flow

Exagen Inc. generates limited operating cash flow of $-12.34M, signaling weaker underlying cash strength.

$-12.34M

Free Cash Flow

Exagen Inc. generates weak or negative free cash flow of $-13.38M, restricting financial flexibility.

$-13.38M

FCF Per Share

Each share generates $-0.52 in free cash annually.

$-0.52

FCF Yield

XGN converts -13.37% of its market value into free cash.

-13.37%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.99

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.26

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.85

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.34

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.09

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.46

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.26

vs 25 benchmark

ROA

Return on assets percentage

-0.33

vs 25 benchmark

ROCE

Return on capital employed

-0.34

vs 25 benchmark

How XGN Stacks Against Its Sector Peers

MetricXGN ValueSector AveragePerformance
P/E Ratio-4.9930.85 Better (Cheaper)
ROE-125.60%473.00% Weak
Net Margin-25.14%5192.00% Weak
Debt/Equity2.090.12 Weak (High Leverage)
Current Ratio3.465.76 Strong Liquidity
ROA-32.83%-1414.00% (disorted) Weak

XGN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Exagen Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-6.92%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

29.83%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

43.22%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ